BRIEF-Veru Receives FDA Agreement To Advance Veru-111 Into Phase 3 Study In Hospitalized Covid-19 Patients At High Risk For Acu
BRIEF-Veru Receives FDA Agreement To Advance Veru-111 Into Phase 3 Study In Hospitalized Covid-19 Patients At High Risk For Acu
March 1 (Reuters) - Veru Inc :
* VERU RECEIVES FDA AGREEMENT TO ADVANCE VERU-111 INTO PHASE 3 STUDY IN HOSPITALIZED COVID-19 PATIENTS AT HIGH RISK FOR ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS)
* VERU INC - VERU COMPLETES EXPEDITED END OF PHASE 2 TRIAL MEETING WITH FDA
* VERU INC - PHASE 3 CLINICAL STUDY EXPECTED TO BEGIN IN APRIL 2021 WITH CLINICAL RESULTS EXPECTED IN CALENDAR Q4 2021
* VERU INC - FDA AGREES TO ADVANCE VERU-111 INTO PHASE 3 CLINICAL STUDY IN HOSPITALIZED HIGH RISK COVID-19 PATIENTS TO CONFIRM POTENTIAL BENEFIT & RISK
* VERU -FDA AGREES CLINICAL FINDINGS SUGGEST CLINICALLY MEANINGFUL BENEFIT FOR USE OF VERU-111 IN HOSPITALIZED COVID-19 PATIENTS AT HIGH RISK FOR ARDS
Source text for Eikon: Further company coverage:
((Reuters.Briefs@thomsonreuters.com;)
路透3月1日电-Veru Inc:*VERU获得食品和药物管理局的同意,将VERU-111推进到住院的新冠肺炎急性呼吸窘迫综合征高危患者的3期研究*Veru Inc-Veru完成与FDA的第二阶段试验会议的加速结束*Veru Inc-3期临床研究预计将于2021年4月开始,临床结果预计将于2021年第四季度公布*VERU INC-FDA同意将VERU-111推进到住院的高危新冠肺炎患者的3期临床研究,以确认潜在的益处和风险*VERU-FDA同意临床研究结果表明,在住院的新冠肺炎患者中使用VERU-111对急性呼吸窘迫综合征的高危患者有临床意义的益处Eikon的源文本:进一步的公司报道:(Reurs.Briefs@thomsonreurs.com;)
译文内容由第三方软件翻译。